Antengene Corporation (SEHK: 6996.HK) is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicine. They are committed to an 'combo-only' R&D strategy and building a pipeline of 13 clinical assets, including 8 global rights assets and 5 assets with rights for Asia Pacific markets including Mainland China, Australia, South Korea and certain Southeast Asian countries. Their vision is to treat patients beyond borders and help them live longer, healthier lives by developing and commercializing first-in-class/best-in-class oncology therapies.
Serves as the central hub for strategic decision-making, research and development coordination, corporate governance, and global operational management.
Located in a modern business park, Vanke Centre, likely featuring contemporary office spaces designed to foster collaboration and innovation among its research, clinical, and corporate teams.
Emphasizes scientific rigor, innovation, collaboration, and a patient-first approach. The culture likely supports dynamic R&D efforts and cross-functional teamwork required in the biopharmaceutical industry.
Shanghai is a major and rapidly growing hub for biotechnology and pharmaceutical innovation in China and globally, providing access to talent, research institutions, and investment opportunities.
Antengene Corporation has established a significant presence across the Asia-Pacific region and is expanding globally. Key functions supported globally include clinical research and development, regulatory affairs, manufacturing liaison, business development, and commercial operations. Their primary focus markets are Mainland China, Australia, South Korea, Taiwan, Hong Kong, and ASEAN countries.
15F, Block B, Vanke Centre, No. 700 Shenchang Road
Shanghai
Shanghai
China
Address: Unit 702, 7/F, Lee Garden Two, 28 Yun Ping Road, Causeway Bay, Hong Kong
Supports corporate finance, investor relations, and strategic partnerships within the Greater China region and internationally.
Address: 1 Fusionopolis Place, #03-20 Galaxis (West Lobby), Singapore 138522
To advance Antengene's pipeline and commercialize approved therapies within Singapore and the broader ASEAN region.
Address: Antengene Korea Ltd., #1001, 10F, Signature Towers Seoul (East), 100 Cheonggyecheon-ro, Jung-gu, Seoul, Republic of Korea
Focuses on local clinical development, patient access programs, and market entry strategies for South Korea.
Address: Antengene Australia Pty Ltd., Suite 2, Level 10, 3 Bowen Crescent, Melbourne VIC 3004, Australia
Facilitates clinical research and development activities in the Oceania region, contributing to global drug development programs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Antengene' leadership includes:
Antengene has been backed by several prominent investors over the years, including:
Antengene has actively strengthened its executive team with key appointments over the past year to support its growth and strategic objectives in the oncology sector.
Discover the tools Antengene uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Antengene Corporation likely utilizes a standard professional email format, commonly combining the employee's first initial and last name, or full first name and last name, with their company domain.
[firstinitial][lastname]@antengene.com or [firstname].[lastname]@antengene.com
Format
jmei@antengene.com
Example
85%
Success rate
Antengene Press Release / PR Newswire • July 8, 2024
Antengene Corporation announced that the New Drug Applications (NDAs) for selinexor (XPOVIO®) in combination with dexamethasone for the treatment of adult patients with relapsed and/or refractory multiple myeloma have been accepted for review by regulatory authorities in Thailand and Malaysia....more
Antengene Press Release / PR Newswire • May 27, 2024
Antengene announced that the first patient has been dosed in the Phase I 'ATOM' trial of ATG-018, a small molecule ATR inhibitor, in patients with advanced solid tumors and hematological malignancies in Australia....more
Antengene Press Release / PR Newswire • January 29, 2024
Antengene Corporation Limited announced the appointment of Mr. Brian A. Campbell as Chief Business Officer (CBO), effective January 29, 2024. Mr. Campbell will be responsible for global business development, corporate strategy, and commercial planning....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Antengene, are just a search away.